In the war against solid tumors arsenic trioxide needs partners

Subbayan Pochi, Bach Ardalan

Research output: Contribution to journalReview article

23 Citations (Scopus)

Abstract

In the past decade, the therapeutic potential of arsenic trioxide (ATO) in the treatment of acute promyelocytic leukemia (APL) was recognized. This encouraged other investigators to test the efficacy of ATO in the management of other hematological and solid tumor malignancies. Notably, as a single agent, arsenic trioxide did not benefit patients diagnosed with solid tumors. However, when it was combined with other agents, treatment benefit emerged. In this article, we have summarized the outcome of clinical trials that used arsenic trioxide as a single agent as well as in combination settings in patients diagnosed with solid tumors. We have also reviewed possible additional mechanisms by which ATO may be useful as a chemosensitizer in combination therapy. We hope that our review will encourage clinical investigators to rationally combine ATO with additional chemotherapeutic agents in treating patients diagnosed with solid tumors.

Original languageEnglish (US)
Pages (from-to)363-371
Number of pages9
JournalJournal of Gastrointestinal Cancer
Volume45
Issue number3
DOIs
StatePublished - Sep 1 2014

Fingerprint

Neoplasms
Research Personnel
Acute Promyelocytic Leukemia
Therapeutics
Warfare
arsenic trioxide
Clinical Trials

ASJC Scopus subject areas

  • Oncology
  • Gastroenterology

Cite this

In the war against solid tumors arsenic trioxide needs partners. / Pochi, Subbayan; Ardalan, Bach.

In: Journal of Gastrointestinal Cancer, Vol. 45, No. 3, 01.09.2014, p. 363-371.

Research output: Contribution to journalReview article

@article{c6a140a719404788b724ae5128f0cf4b,
title = "In the war against solid tumors arsenic trioxide needs partners",
abstract = "In the past decade, the therapeutic potential of arsenic trioxide (ATO) in the treatment of acute promyelocytic leukemia (APL) was recognized. This encouraged other investigators to test the efficacy of ATO in the management of other hematological and solid tumor malignancies. Notably, as a single agent, arsenic trioxide did not benefit patients diagnosed with solid tumors. However, when it was combined with other agents, treatment benefit emerged. In this article, we have summarized the outcome of clinical trials that used arsenic trioxide as a single agent as well as in combination settings in patients diagnosed with solid tumors. We have also reviewed possible additional mechanisms by which ATO may be useful as a chemosensitizer in combination therapy. We hope that our review will encourage clinical investigators to rationally combine ATO with additional chemotherapeutic agents in treating patients diagnosed with solid tumors.",
author = "Subbayan Pochi and Bach Ardalan",
year = "2014",
month = "9",
day = "1",
doi = "10.1007/s12029-014-9617-8",
language = "English (US)",
volume = "45",
pages = "363--371",
journal = "Journal of Gastrointestinal Cancer",
issn = "1941-6628",
publisher = "Humana Press",
number = "3",

}

TY - JOUR

T1 - In the war against solid tumors arsenic trioxide needs partners

AU - Pochi, Subbayan

AU - Ardalan, Bach

PY - 2014/9/1

Y1 - 2014/9/1

N2 - In the past decade, the therapeutic potential of arsenic trioxide (ATO) in the treatment of acute promyelocytic leukemia (APL) was recognized. This encouraged other investigators to test the efficacy of ATO in the management of other hematological and solid tumor malignancies. Notably, as a single agent, arsenic trioxide did not benefit patients diagnosed with solid tumors. However, when it was combined with other agents, treatment benefit emerged. In this article, we have summarized the outcome of clinical trials that used arsenic trioxide as a single agent as well as in combination settings in patients diagnosed with solid tumors. We have also reviewed possible additional mechanisms by which ATO may be useful as a chemosensitizer in combination therapy. We hope that our review will encourage clinical investigators to rationally combine ATO with additional chemotherapeutic agents in treating patients diagnosed with solid tumors.

AB - In the past decade, the therapeutic potential of arsenic trioxide (ATO) in the treatment of acute promyelocytic leukemia (APL) was recognized. This encouraged other investigators to test the efficacy of ATO in the management of other hematological and solid tumor malignancies. Notably, as a single agent, arsenic trioxide did not benefit patients diagnosed with solid tumors. However, when it was combined with other agents, treatment benefit emerged. In this article, we have summarized the outcome of clinical trials that used arsenic trioxide as a single agent as well as in combination settings in patients diagnosed with solid tumors. We have also reviewed possible additional mechanisms by which ATO may be useful as a chemosensitizer in combination therapy. We hope that our review will encourage clinical investigators to rationally combine ATO with additional chemotherapeutic agents in treating patients diagnosed with solid tumors.

UR - http://www.scopus.com/inward/record.url?scp=85027923556&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85027923556&partnerID=8YFLogxK

U2 - 10.1007/s12029-014-9617-8

DO - 10.1007/s12029-014-9617-8

M3 - Review article

C2 - 24825822

AN - SCOPUS:85027923556

VL - 45

SP - 363

EP - 371

JO - Journal of Gastrointestinal Cancer

JF - Journal of Gastrointestinal Cancer

SN - 1941-6628

IS - 3

ER -